In biotechnology, timing is everything. Whether advancing a novel therapy or scaling a platform, companies often reach a pivotal point: go public or sell. Increasingly, biotech executives are choosing ...
The ups and downs of the M&A and financing markets over the past few years, particularly in the emerging companies (EC) and venture capital (VC) sector, have demonstrated the importance of emerging ...
A lot of scientific and popular decision-making literature is couched in a dual-process model [1]. The dual-process model pits the relatively automatic, heuristic-driven, and unconscious System 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback